如何治疗儿童急性白血病长期生存者
儿童白血病生存者成年人群因治疗进步而扩大,但面临长期并发症风险。综合随访项目在生存者照护中起关键作用。长期并发症的主要决定因素是随时间累积的治疗负担,复发化疗、中枢神经系统放疗、造血干细胞移植和全身放疗与更高风险相关。早期诊断可改善多种远期并发症的管理。
要点
- 治疗负担是儿童白血病生存者长期并发症的主要决定因素。
- 复发化疗、中枢神经系统放疗、造血干细胞移植和全身放疗与更高长期并发症风险相关。
- 早期诊断可改善蒽环类药物相关心肌病、二次癌症、代谢综合征、发育缺陷和不育等远期并发症的管理。
核心结论
- 儿童白血病生存者长期并发症的主要决定因素是随时间累积的治疗负担。
- 早期诊断可改善多种远期并发症的管理。
- 单独化疗者长期并发症风险较低,但最佳长期随访仍不明确。
- 新型免疫治疗和靶向治疗通常短期安全性较好,但仍需仔细的长期毒性监测。
- 理解长期并发症遗传易感性的进展可能实现个体化治疗策略和优化随访项目。
研究设计与样本
- 原文为综述,未报告检索范围。
主要发现
- 复发化疗、中枢神经系统放疗、造血干细胞移植和全身放疗与更高长期并发症风险相关。
- 其他参数包括年龄和性别等临床特征以及环境、遗传和社会经济因素,可帮助分层长期并发症风险并组织随访项目。
- 全身放疗是与更差长期毒性特征相关的治疗,伴随广泛并发症。
- 单独化疗者长期并发症风险较低,但最佳长期随访仍不明确。
- 新型免疫治疗和靶向治疗通常短期安全性较好,但仍需仔细的长期毒性监测。
关键数值与推荐
- 长期并发症的主要决定因素是随时间累积的治疗负担。
- 早期诊断可改善蒽环类药物相关心肌病、二次癌症、代谢综合征、发育缺陷和不育等远期并发症的管理。
临床怎么用
- 综合随访项目在儿童白血病生存者照护中起关键作用。
- 年龄和性别等临床特征以及环境、遗传和社会经济因素可帮助分层长期并发症风险并组织随访项目。
- 单独化疗者最佳长期随访仍不明确。
- 新型免疫治疗和靶向治疗仍需仔细的长期毒性监测。
局限性
- 单独化疗者最佳长期随访仍不明确。
- 新型免疫治疗和靶向治疗仍需仔细的长期毒性监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The population of survivors of childhood leukemia who reach adulthood is growing due to improved therapy. However, survivors are at risk of long-term complications. Comprehensive follow-up programs play a key role in childhood leukemia survivor care. The major determinant of long-term complications is the therapeutic burden accumulated over time. Relapse chemotherapy, central nervous system irradiation, hematopoietic stem cell transplantation, and total body irradiation are associated with greater risk of long-term complications. Other parameters include clinical characteristics such as age and sex as well as environmental, genetic, and socioeconomic factors, which can help stratify the risk of long-term complications and organize follow-up program. Early diagnosis improves the management of several late complications such as anthracycline-related cardiomyopathy, secondary cancers, metabolic syndrome, development defects, and infertility. Total body irradiation is the treatment associated with worse long-term toxicity profile with a wide range of complications. Patients treated with chemotherapy alone are at a lower risk of long-term complications, although the optimal long-term follow-up remains unclear. Novel immunotherapies and targeted therapy are generally associated with a better short-term safety profile but still require careful long-term toxicity monitoring. Advances in understanding genetic susceptibility to long-term complications could enable tailored therapeutic strategies for leukemia treatment and optimized follow-up programs.
引用
- Saultier P, Michel G. How I treat long-term survivors of childhood acute leukemia. Blood. 2024. PMID: 38227937. doi:10.1182/blood.2023019804
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。